CoChat

INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION

MEYERLE, CATHERINE B., FREUND, K BAILEY, ITURRALDE, DIANA, SPAIDE, RICHARD F., SORENSON, JOHN A., SLAKTER, JASON S., KLANCNIK, JAMES M., FISHER, YALE L., COONEY, MICHAEL J., YANNUZZI, LAWRENCE A. · 2007 · Retina
Cited by 88

The DOI matches its Crossref record.

Abstract

OBJECTIVE: To evaluate the short-term visual acuity and anatomic responses after intravitreal bevacizumab (Avastin, Genentech) treatment in patients with retinal angiomatous proliferation (RAP). METHODS: The authors conducted a retrospective review of consecutive patients with newly diagnosed or recurrent RAP treated with intravitreal bevacizumab (1.25 mg) during a 3-month period. Complete ocular examination was performed at baseline and follow-up visits. Interval data were analyzed statistically at 1 and 3 months follow-up. RESULTS: Twenty-three eyes of 23 patients underwent intravitreal bevacizumab treatment. The mean age of patients was 81.1 years, median baseline visual acuity of treated eyes was 20/80 (range 20/25-20/800), and mean baseline central macular thickness was 335 mum (optical coherence tomography was available for 22 eyes). Nine eyes had retinal pigment epithelial detachments (PEDs) at baseline. At 1-month follow-up, the median acuity improved to 20/60 (range 20/30-20/400) (P < 0.001), mean central macular thickness decreased to 202 microm (P < 0.001), and PED was present in only 2 eyes (P = 0.016). Seven of 23 eyes at 1 month (30.4%) had improved visual acuity, defined as halving of the visual angle, and no eyes had worse acuity, defined as doubling of the visual angle. Of the 17 eyes available for 3-month follow-up, 5 eyes (29.4%) had better visual acuity, 1 eye (5.9%) had worse acuity, and the remaining 11 (64.7%) had the same acuity. The median visual acuity at month 3 was 20/60 (range 20/25-20/400). There were no thromboembolic phenomena, endophthalmitis cases, retinal detachments, or any other adverse events. CONCLUSION: Treatment of RAP with intravitreal bevacizumab during this retrospective review resulted in a significant decrease in macular thickness and improvement or stabilization of visual acuity. Further long-term investigation is warranted given the promising short-term results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318030ea80

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 88

Metadata

Authors
MEYERLE, C. B., FREUND, K. B., ITURRALDE, D., SPAIDE, R. F., SORENSON, J. A., SLAKTER, J. S., KLANCNIK, J. M., FISHER, Y. L., COONEY, M. J., & YANNUZZI, L. A.
Venue
Retina
Published
2007-04
Volume
27
Issue
4
Pages
451-457
ISSN
0275-004X (ISSN-L)
OpenAlex
W1999946691
Cited by
88
References
0
FWCI
14.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e318030ea80
The paper
MEYERLE, C. B., FREUND, K. B., ITURRALDE, D., SPAIDE, R. F., SORENSON, J. A., SLAKTER, J. S., KLANCNIK, J. M., FISHER, Y. L., COONEY, M. J., & YANNUZZI, L. A. (2007). INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION. Retina. https://doi.org/10.1097/iae.0b013e318030ea80

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.